Effect of IBD medications on COVID-19 outcomes: results from an international registry.

ABSTRACT:

Objective

We sought to evaluate COVID-19 clinical course in patients with IBD treated with different medication classes and combinations.

Design

Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD) is a large, international registry created to monitor outcomes of IBD patients with confirmed COVID-19. We used multivariable regression with a generalised estimating equation accounting for country as a random effect to analyse the association of different medication classes with severe COVID-19, defined as intensive care unit admission, ventilator use and/or death.

Results

1439 cases from 47 countries were included (mean age 44.1 years, 51.4% men) of whom 112 patients (7.8%) had severe COVID-19. Compared with tumour

SUBMITTER: Ungaro RC 

PROVIDER: S-EPMC8136807 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature